In response to W5’s investigation, here is a statement issued Saturday, September 30, from Ethicon, a subsidiary of Johnson & Johnson:

We empathize with all women suffering from stress urinary incontinence, a condition that can be serious and debilitating. Pelvic mesh devices have helped millions of women suffering from stress urinary incontinence. There are limited treatment choices for women with stress urinary incontinence seeking to improve their quality of life, including surgical treatment with implantable mesh, which is backed by years of clinical research and is considered by most doctors to be the gold standard treatment. Ethicon is confident in the positive impact our pelvic mesh products have had on the vast majority of women who have chosen this treatment option. In addition, the evidence shows that Ethicon acted appropriately and responsibly in the research, development and marketing of its TVT device for the treatment of stress urinary incontinence.”

Despite repeated requests, C. R. Bard, Inc. did not provide comment.